NCT04238650View on ClinicalTrials.gov

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

December 27, 2019

Study Completion Date

December 27, 2019

Conditions
Healthy VolunteersMaleJapanese
Interventions
DRUG

MB02 (Bevacizumab Biosimilar)

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion

DRUG

EU approved Avastin®

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion

Trial Locations (1)

812-0025

SOUSEIKAI Hakata Clinic, Fukuoka

All Listed Sponsors
lead

mAbxience Research S.L.

INDUSTRY

NCT04238650 - A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter